Pierre Fabre Fights Off Rivals For Rights To Atara's Allogeneic T-Cell Therapy
Tab-Cel Granted Accelerated Assessment By EMA For Rare Cancer
After paying $45m upfront, the French firm has beaten off considerable competition to seal the European, Middle East and African rights to tabelecleucel which will be filed next month for Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
